Prioritize drug targets with evidence, not spreadsheets.
You have fifty candidates and budget for three. Nuclens scores every target on the same criteria, shows you exactly why each one ranks where it does, and gives your team a defensible shortlist in minutes instead of a month of slide-building.
Free to search and rank. Pay only when you generate a full decision report.
What is drug target prioritization?
Drug target prioritization is ranking candidate targets by how likely each is to yield a safe, effective and differentiated drug. It rests on target assessment: scoring each target on disease linkage, druggability or tractability, expression, safety, clinical precedent and competition. Nuclens runs that assessment across thousands of oncology targets and returns an explainable ranking.
Target assessment shouldn’t depend on who built the spreadsheet.
Most target prioritization still happens in a hand-built scoring matrix. Different people, different weights, different sources, and weeks to refresh it.
| Task | The manual way | With Nuclens |
|---|---|---|
| Define criteria | Debate weights in meetings, rebuild the matrix each program | Six standard dimensions, adjusted by your plain-English criteria |
| Gather evidence | Each scientist pulls data for their share of the targets | Evidence for every target pulled from the same six sources |
| Score consistently | Subjective scores that drift between reviewers | Same rubric for every target; same inputs, same candidate pool |
| Explain the ranking | Slide decks that summarize, without the sources | Per-target scorecard with every value linked to its source |
| Keep it current | Re-do the analysis when a trial or paper lands | Sources refreshed continuously; re-run in a minute |
| Result | A matrix that takes weeks and ages fast | A ranked, explainable shortlist, on demand |
What Nuclens screens, every time you ask.
Example: in breast cancer, 4,328 cell-surface proteins show detectable tumor staining in Human Protein Atlas immunohistochemistry. See the ranked breast cancer targets →
Drug target prioritization in three steps.
Bring your candidates or your criteria
Paste the targets you are weighing, or describe the profile you want and let Nuclens build the list.
Score on six evidence dimensions
Accessibility, normal-tissue safety, tumor specificity, clinical maturity, internalization and competitive landscape, each with its own transparent sub-score.
Compare, challenge, decide
See side-by-side scorecards, open any source, and generate a full target assessment report for the program review.
What a good target assessment actually weighs.
Target prioritization is choosing which candidates deserve scarce lab time and budget. The best-known framework, AstraZeneca’s 5R (Cook et al., 2014), is built around one lesson: most late failures trace back to the target itself. These are the dimensions that matter most.
Link to disease
Is there causal evidence (human genetics, functional screens) that the target drives the disease, not just correlates with it?
Druggability & tractability
Can your modality actually reach and act on it? For radioligands and antibodies that means the target must be on the cell surface.
Expression & specificity
Is it on the diseased tissue, across most patients, and absent from organs you can’t afford to hit?
Safety
Where else is it expressed, and what happens when it is modulated? For radioligands, dose-limiting organs decide the therapeutic window.
Clinical precedent
Has anyone drugged it? Precedent lowers biological risk but raises competition.
Competitive landscape
Is the space crowded or open? Differentiation drives commercial value.
Druggability vs. tractability. Druggability classically means the likelihood that a protein can be modulated by a drug-like small molecule, the idea behind the "druggable genome" (Hopkins & Groom, 2002). Tractability is broader and modality-specific: an undruggable protein for small molecules can be highly tractable for an antibody or a radioligand if it sits on the cell surface. Nuclens assesses target druggability through that modality lens.
What is target intelligence? Target intelligence is the continuously updated picture of everything known about a target: its biology, expression, clinical programs, competitors and new literature. A one-off target assessment goes stale the moment a new trial posts. Nuclens keeps the evidence current, so re-prioritizing takes a minute, not a new project.
Frameworks that work. Alongside the 5R framework, the GOT-IT recommendations give academic teams a structured target assessment checklist. Nuclens applies the same idea, a fixed rubric applied the same way every time, and adds the radioligand-specific dimensions most frameworks leave out. See the full six-criteria framework for radioligand targets.
Give your team its weeks back.
Walk into portfolio review with a ranked list and the evidence behind every position, not a gut call.
Stop rebuilding the scoring matrix for every program. Apply the same rubric to every candidate and spend your time on the edge cases.
Track crowded vs. open targets and spot white space before your competitors do.
Common questions
What is target prioritization in drug discovery?
Target prioritization is ranking candidate drug targets by how likely they are to produce a safe, effective and differentiated drug, so that limited lab time and budget go to the best bets. It follows target identification and precedes experimental validation.
What is the difference between target assessment and target prioritization?
Target assessment evaluates one target against a set of criteria: disease link, tractability, safety, precedent and competition. Target prioritization compares those assessments across many targets and ranks them. Nuclens does both: a scorecard per target, and a ranking across the list.
How do you assess target druggability?
For small molecules, druggability depends on binding pockets and chemical precedent. For biologics, ADCs and radioligands, the key question is accessibility: the target has to be on the cell surface and expressed on the diseased tissue. Nuclens scores accessibility from UniProt localization and tumor expression from the Human Protein Atlas.
What is target intelligence?
Target intelligence is a continuously updated view of a target’s biology, expression, clinical activity, competitors and literature. It turns target assessment from a one-off report into something you can re-run whenever the evidence changes.
Can I use my own prioritization criteria?
Yes. Describe your constraints in plain English, for example "alpha emitter, avoid bone marrow expression, novel targets only". Nuclens translates them into filters and adjusts the ranking.
Is the scoring a black box?
No. Every target gets a six-dimension scorecard, and every underlying value is shown with its source and version. Hard filters are deterministic, so the same criteria return the same candidate pool every time.
Stop debating the matrix. Start from the evidence.
Score and rank your candidate targets free. Pay only when a target is worth a full assessment report.